Protagonist Therapeutics, Inc. (NasdaqGM: PTGX)
Health Care · Biotechnology · US
$154.32
+2.41% today · +168.5% 1Y
Protagonist Therapeutics, Inc. (NasdaqGM: PTGX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $9.99B and employs 132 people.
Over the last twelve months the share price has gained 168.5%, trading between 54.50 and 158.95.
Tweenvest scores Protagonist Therapeutics, Inc. across four factors: quality 56/100, value 15/100, growth 62/100. Its strongest factor is growth.
PTGX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.99B
- Revenue (TTM)
- $281.99M
- P/E
- 126.37
- EPS
- 1.22
- Dividend yield
- —
- Beta (5Y)
- 1.79
- 52-week high
- $158.95
- 52-week low
- $54.50
- Avg volume (3M)
- —
- Shares outstanding
- 64.71M
- Employees
- 132
- Next earnings
- —
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
- ISIN
- US74366E1029
- Founded
- 2006
- Listed since
- Aug 11, 2016
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.